Migdal Insurance & Financial Holdings Ltd. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,252 shares of the medical device company’s stock after selling 110 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in DexCom were worth $387,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Great West Life Assurance Co. Can lifted its position in DexCom by 141.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 24,305 shares of the medical device company’s stock worth $2,780,000 after buying an additional 14,225 shares in the last quarter. Virginia Retirement Systems ET AL lifted its position in DexCom by 230.6% during the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock worth $1,929,000 after buying an additional 11,300 shares in the last quarter. Two Sigma Advisers LP lifted its position in DexCom by 1,493.1% during the fourth quarter. Two Sigma Advisers LP now owns 694,814 shares of the medical device company’s stock worth $83,239,000 after buying an additional 651,200 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its position in DexCom by 33.2% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 181,252 shares of the medical device company’s stock valued at $21,714,000 after purchasing an additional 45,149 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in DexCom in the fourth quarter valued at $442,000. 96.51% of the stock is currently owned by institutional investors.
DXCM traded down $2.11 on Wednesday, hitting $118.60. 1,118,250 shares of the company were exchanged, compared to its average volume of 1,302,783. DexCom, Inc. has a twelve month low of $86.55 and a twelve month high of $156.16. The stock has a market capitalization of $10.81 billion, a price-to-earnings ratio of 395.33 and a beta of 0.73. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.12. The business had revenue of $280.50 million during the quarter, compared to analysts’ expectations of $246.10 million. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The business’s quarterly revenue was up 52.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) EPS. On average, research analysts anticipate that DexCom, Inc. will post 0.77 earnings per share for the current year.
DXCM has been the topic of a number of research analyst reports. Cowen lifted their target price on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Friday, February 22nd. Morgan Stanley lifted their target price on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research report on Monday, February 25th. Canaccord Genuity lifted their target price on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, February 22nd. UBS Group cut their price objective on DexCom from $150.00 to $140.00 and set a “neutral” rating on the stock in a report on Tuesday, April 30th. Finally, ValuEngine downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Monday, April 1st. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. DexCom has a consensus rating of “Buy” and an average target price of $152.25.
In related news, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $141.56, for a total value of $56,624.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Steven Robert Pacelli sold 3,596 shares of the company’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $140.04, for a total value of $503,583.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,460 shares of company stock valued at $13,409,877. Insiders own 1.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Position Reduced by Migdal Insurance & Financial Holdings Ltd.” was published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://sundanceherald.com/2019/05/29/migdal-insurance-financial-holdings-ltd-has-387000-stake-in-dexcom-inc-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: Growth Stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.